<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="2375"><DrugName>nateglinide</DrugName><DrugNamesKey><Name id="42763871">Fastic</Name><Name id="42763875">Starlix</Name><Name id="42763876">Starsis</Name><Name id="42763872">Stasis</Name><Name id="42993948">Tang Rui</Name><Name id="42753447">nateglinide</Name></DrugNamesKey><DrugSynonyms><Name><Value>A-4166</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AY-4166</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nateglinide</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>SDZ-DJN-608</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Fastic</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Stasis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>YM-026</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DJN-608</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Starlix</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Starsis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>senaglinide</Value></Name><Name><Value>Tang Rui</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>105816-04-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13794">Ajinomoto Co Inc</CompanyOriginator><CompaniesPrimary><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Company id="25218">Aventis Pharma AG</Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Company id="23137">Novartis AG</Company><Company id="13794">Ajinomoto Co Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="19658">Sankyo Co Ltd</Company><Company id="23970">Britannia Pharmaceuticals Ltd</Company><Company id="26133">Roussel Morishita Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2375" type="Drug"><TargetEntity id="127137" type="siDrug">Nateglinide</TargetEntity></SourceEntity><SourceEntity id="1017506" type="Company"><TargetEntity id="4295880584" type="organizationId">Daiichi Sankyo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="13794" type="Company"><TargetEntity id="4295877401" type="organizationId">Ajinomoto Co Inc</TargetEntity></SourceEntity><SourceEntity id="17101" type="Company"><TargetEntity id="4295881034" type="organizationId">Ildong Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="18278" type="Company"><TargetEntity id="4295877793" type="organizationId">Mochida Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19658" type="Company"><TargetEntity id="5000284515" type="organizationId">Sankyo Co Ltd Pharmaceutical</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="23970" type="Company"><TargetEntity id="4296070333" type="organizationId">Britannia Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="25218" type="Company"><TargetEntity id="4296758779" type="organizationId">Aventis Pharma AG</TargetEntity></SourceEntity><SourceEntity id="26133" type="Company"><TargetEntity id="5035523998" type="organizationId">Roussel Morishita Co Ltd</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="92" type="Action"><TargetEntity id="360" type="Mechanism">Calcium Channel Activators</TargetEntity></SourceEntity><SourceEntity id="3246" type="Action"><TargetEntity id="604" type="Mechanism">Insulin-Releasing Agents</TargetEntity></SourceEntity><SourceEntity id="314" type="Action"><TargetEntity id="4392" type="Mechanism">Potassium Channel Subfamily K Blockers</TargetEntity><TargetEntity id="1642" type="Mechanism">Calcium-Activated K(Ca) Channel Blockers</TargetEntity><TargetEntity id="372" type="Mechanism">K(ATP) Channel Blockers</TargetEntity><TargetEntity id="367" type="Mechanism">Potassium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Non-insulin dependent diabetes - Japan - Aug-1999</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsPrimary><ActionsPrimary><Action id="92">Calcium channel stimulator</Action><Action id="314">Potassium channel inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="3246">Insulin release stimulator</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-08-20T10:26:16.000Z</LastModificationDate><ChangeDateLast>2018-08-20T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Nateglinide (Fastic; Starlix; Starsis) is a novel hypoglycemic agent discovered by &lt;ulink linkID="13794" linkType="Company"&gt;Ajinomoto&lt;/ulink&gt;, and developed and launched by &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; and Yamanouchi  (now &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas&lt;/ulink&gt;). Nateglinide stimulates insulin secretion from the pancreas by blocking potassium channels on pancreatic beta-cells, which leads to the activation of calcium channels and the secretion of insulin. As a monotherapy, the product is indicated as an adjunct to diet and exercise to improve glycemic control in patients with non-insulin dependent diabetes mellitus (NIDDM; type 2 diabetes). It is also indicated in combination with alpha-glucosidase inhibtors, biguanides (including &lt;ulink linkID="6050" linkType="Drug"&gt;metformin&lt;/ulink&gt;) or thiazolidines, when diet and exercise  or the single agent does not result in adequate glycemic control [&lt;ulink linkID="483765" linkType="Reference"&gt;483765&lt;/ulink&gt;], [&lt;ulink linkID="972909" linkType="Reference"&gt;972909&lt;/ulink&gt;], [&lt;ulink linkID="1747410" linkType="Reference"&gt;1747410&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nateglinide was launched in Japan in August 1999 by Yamanouchi [&lt;ulink linkID="338592" linkType="Reference"&gt;338592&lt;/ulink&gt;]. In February 2001, US launch took place [&lt;ulink linkID="392881" linkType="Reference"&gt;392881&lt;/ulink&gt;], [&lt;ulink linkID="398723" linkType="Reference"&gt;398723&lt;/ulink&gt;], [&lt;ulink linkID="420293" linkType="Reference"&gt;420293&lt;/ulink&gt;], and European launches began in May 2001 [&lt;ulink linkID="1355445" linkType="Reference"&gt;1355445&lt;/ulink&gt;]. In 2003, the FDA additionally approved the use of nateglinide in combination with a thiazolidinedione  in patients with type 2 diabetes who are not adequately controlled after a therapeutic response to a thiazolidinedione [&lt;ulink linkID="588269" linkType="Reference"&gt;588269&lt;/ulink&gt;].  In November 2007, nateglinide was approved for use in Japan in combination with biguanides [&lt;ulink linkID="851523" linkType="Reference"&gt;851523&lt;/ulink&gt;]. In December 2008, nateglinide was approved for use in combination with thiazolidines in Japan [&lt;ulink linkID="972909" linkType="Reference"&gt;972909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, Ajinomoto and Astellas planned to file for Japanese approval for the combination of nateglinide plus DPP-IV inhibitors in 1H14 [&lt;ulink linkID="1338884" linkType="Reference"&gt;1338884&lt;/ulink&gt;]; in July 2014, Astellas filed for Japanese approval  for the combination of nateglinide plus DPP-IV inhibitors [&lt;ulink linkID="1582289" linkType="Reference"&gt;1582289&lt;/ulink&gt;]. However, in March 2015, Astellas stated that the NDA was withdrawn for strategic reasons and development discontinued [&lt;ulink linkID="1671405" linkType="Reference"&gt;1671405&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;RE34878 was a reissue of the original product patent &lt;ulink linkID="IN1472110" linkType="Patent"&gt;US-04816484&lt;/ulink&gt; (with a correction), which expired on September 8, 2009. This patent was based on an earlier application filed on March 27, 1986, that was granted on March 28, 1989. The RE34878 patent would normally have expired on March 27, 2006, however, an extension of 1260 days was granted,  extending the expiry date to September 08, 2009 [&lt;ulink linkID="608663" linkType="Reference"&gt;608663&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2004, an ANDA with a Paragraph IV certification was submitted to the FDA for 60 and 120 mg nateglinide tablets   [&lt;ulink linkID="663902" linkType="Reference"&gt;663902&lt;/ulink&gt;]. In September 2009, the FDA granted &lt;ulink linkID="28968" linkType="Company"&gt;Par Pharmaceutical&lt;/ulink&gt; final approval for its 60 and 120 mg dose nateglinide tablets   [&lt;ulink linkID="1040913" linkType="Reference"&gt;1040913&lt;/ulink&gt;]; by November 2009, Par had launched  the 60 mg and 120 mg dose nateglinide tablets [&lt;ulink linkID="1055214" linkType="Reference"&gt;1055214&lt;/ulink&gt;].  In September 2009, ANDA approvals for 60 and 120 mg nateglinide tablets were also granted to &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's&lt;/ulink&gt; and &lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceuticals&lt;/ulink&gt;  [&lt;ulink linkID="1049185" linkType="Reference"&gt;1049185&lt;/ulink&gt;]; by March 2011, Dr Reddy's generic nateglinide was available in the US [&lt;ulink linkID="1308104" linkType="Reference"&gt;1308104&lt;/ulink&gt;]. At that time, &lt;ulink linkID="21717" linkType="Company"&gt;Watson Pharmaceuticals&lt;/ulink&gt; received FDA approval for its generic version of nateglinide tablets (60 and 120 mg)  [&lt;ulink linkID="1245272" linkType="Reference"&gt;1245272&lt;/ulink&gt;]; and by September 2011, Watson had launched its generic product in the US [&lt;ulink linkID="1308106" linkType="Reference"&gt;1308106&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2016, the FDA granted a tentative approval to &lt;ulink linkID="1084114" linkType="Company"&gt;Zydus Pharmaceuticals&lt;/ulink&gt;' generic version of the drug [&lt;ulink linkID="1779456" linkType="Reference"&gt;1779456&lt;/ulink&gt;]; later that month, the FDA granted final approval  for 60 and 120 mg generic nateglinide tablets [&lt;ulink linkID="1779222" linkType="Reference"&gt;1779222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2007, Novartis stated that the basic compound patent covering nateglinide in Germany, France, the UK and Switzerland expired in 2011 [&lt;ulink linkID="785234" linkType="Reference"&gt;785234&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In 2005, &lt;ulink linkID="1074048" linkType="Company"&gt;Jiangsu Deyuan Pharmaceutical&lt;/ulink&gt;, under license from &lt;ulink linkID="1006925" linkType="Company"&gt;Jiangsu Hengrui Medicine&lt;/ulink&gt;, obtained approval for Tang Rui, a tablet formulation of nateglinide, for the treatment of type 2 diabetes. This generic version was approved as a Class 2  drug rather than a Class 3 (generic) drug because it was filed at approximately the same time as the originator drug was filed. Launch took place shortly after [&lt;ulink linkID="1331416" linkType="Reference"&gt;1331416&lt;/ulink&gt;], [&lt;ulink linkID="1331418" linkType="Reference"&gt;1331418&lt;/ulink&gt;], [&lt;ulink linkID="1331463" linkType="Reference"&gt;1331463&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The drug was filed with the FDA in December 1999 [&lt;ulink linkID="351318" linkType="Reference"&gt;351318&lt;/ulink&gt;], and approval was granted in December 2000 [&lt;ulink linkID="394704" linkType="Reference"&gt;394704&lt;/ulink&gt;]. Nateglinide was launched in the US in February 2001 [&lt;ulink linkID="392881" linkType="Reference"&gt;392881&lt;/ulink&gt;], [&lt;ulink linkID="398723" linkType="Reference"&gt;398723&lt;/ulink&gt;], [&lt;ulink linkID="420293" linkType="Reference"&gt;420293&lt;/ulink&gt;]. In 2003, the FDA additionally approved the use of nateglinide in combination with a  thiazolidinedione in patients who are not adequately controlled after a therapeutic response to a thiazolidinedione [&lt;ulink linkID="588269" linkType="Reference"&gt;588269&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;The drug was approved in Europe in April 2001, for use in combination with metformin [&lt;ulink linkID="404307" linkType="Reference"&gt;404307&lt;/ulink&gt;]. In May 2001, the drug was launched in the UK [&lt;ulink linkID="1355445" linkType="Reference"&gt;1355445&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2000, nateglinide received approval in Switzerland [&lt;ulink linkID="384984" linkType="Reference"&gt;384984&lt;/ulink&gt;]; launch occurred in December of that year [&lt;ulink linkID="392881" linkType="Reference"&gt;392881&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;Nateglinide was first launched in Japan in August 1999 by Yamanouchi [&lt;ulink linkID="338592" linkType="Reference"&gt;338592&lt;/ulink&gt;]. In November 2006, a Japanese NDA for concomitant treatment with insulin sensitizers was submitted [&lt;ulink linkID="810416" linkType="Reference"&gt;810416&lt;/ulink&gt;]. In December 2008, nateglinide was approved for use in combination with thiazolidines, which act as insulin sensitizers, in Japan [&lt;ulink linkID="972909" linkType="Reference"&gt;972909&lt;/ulink&gt;]. In January 2006, Astellas filed a Japanese sNDA for nateglinide combined with biguanides for the treatment of post-prandial hyperglycemia in type 2 diabetics [&lt;ulink linkID="655834" linkType="Reference"&gt;655834&lt;/ulink&gt;]; it was approved in November 2007 [&lt;ulink linkID="851523" linkType="Reference"&gt;851523&lt;/ulink&gt;]. By February 2009, the use of nateglinide with &lt;ulink linkID="4126" linkType="Drug"&gt;pioglitazone&lt;/ulink&gt; (Actos) was approved [&lt;ulink linkID="984737" linkType="Reference"&gt;984737&lt;/ulink&gt;]. By October 2012, &lt;ulink linkID="18278" linkType="Company"&gt;Mochida&lt;/ulink&gt; was also marketing the product in Japan under the tradename Fastic [&lt;ulink linkID="1329963" linkType="Reference"&gt;1329963&lt;/ulink&gt;].  At that time, Ajinomoto and Astellas planned to file for approval for the combination of nateglinide plus DPP-IV inhibitors in 1H14 [&lt;ulink linkID="1338884" linkType="Reference"&gt;1338884&lt;/ulink&gt;]. In July 2014, Astellas filed for approval  for the combination of nateglinide plus DPP-IV inhibitors [&lt;ulink linkID="1582289" linkType="Reference"&gt;1582289&lt;/ulink&gt;]. However, by May 2015, Astellas had withdrawn the NDA [&lt;ulink linkID="1658745" linkType="Reference"&gt;1658745&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In September 2003, Ajinomoto was granted approval of nateglinide in China  [&lt;ulink linkID="1261700" linkType="Reference"&gt;1261700&lt;/ulink&gt;]; by February 2012, it had been launched there by marketing partner Novartis [&lt;ulink linkID="1261697" linkType="Reference"&gt;1261697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;Nateglinide was launched in Canada in March 2003 [&lt;ulink linkID="931770" linkType="Reference"&gt;931770&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In December 2000, nateglinide was launched in Brazil [&lt;ulink linkID="392881" linkType="Reference"&gt;392881&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2012, the drug had been launched in Chile as Starlix [&lt;ulink linkID="1351928" linkType="Reference"&gt;1351928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt; In July 2001, the  drug was approved in Taiwan, it was assumed that  launch took place shortly after [&lt;ulink linkID="1517391" linkType="Reference"&gt;1517391&lt;/ulink&gt;], [&lt;ulink linkID="1509402" linkType="Reference"&gt;1509402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, Il Dong launched nateglinide (as Fastic) in  South Korea [&lt;ulink linkID="966663" linkType="Reference"&gt;966663&lt;/ulink&gt;]. In February 2009, &lt;ulink linkID="17101" linkType="Company"&gt;Il Dong&lt;/ulink&gt; planned to submit a filing for the use of nateglinide with pioglitazone in South Korea [&lt;ulink linkID="984737" linkType="Reference"&gt;984737&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In June 2001, Novartis announced its intention to start the NAVIGATOR trial. This trial was to investigate the effect of nateglinide in combination with the antihypertensive &lt;ulink linkID="2773" linkType="Drug"&gt;valsartan&lt;/ulink&gt; on progression from impaired glucose tolerance (IGT) to type 2 diabetes. Monotherapy of each drug was to be compared with combinations and with placebo. An extension phase was to investigate the effect of nateglinide on cardiovascular morbidity and mortality over 5 to 6 years. Of 7500 patients recruited, 2500 were to be over 55 years old with cardiovascular disease and the rest were to have at least one risk factor for cardiovascular disease [&lt;ulink linkID="412601" linkType="Reference"&gt;412601&lt;/ulink&gt;]. By January 2006, the NAVIGATOR  study was ongoing. The trial will measure whether the combination can prevent IGT patients from developing clinical diabetes and assess whether treatment can reduce the incidence of cardiovascular disease in these patients. At that time, results were expected in 2009 [&lt;ulink linkID="651833" linkType="Reference"&gt;651833&lt;/ulink&gt;], [&lt;ulink linkID="654396" linkType="Reference"&gt;654396&lt;/ulink&gt;], [&lt;ulink linkID="654575" linkType="Reference"&gt;654575&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In October 2012, a phase III study was planned in Japan to assess the combination of nateglinide and a DPP-IV inhibitor [&lt;ulink linkID="1329963" linkType="Reference"&gt;1329963&lt;/ulink&gt;]. In May 2013,  the drug was listed as being in phase III development for type 2 diabetes [&lt;ulink linkID="1449162" linkType="Reference"&gt;1449162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, data were reported from a Japanese clinical trial in 295 patients with type 2 diabetes showing that the combined use of nateglinide and &lt;ulink linkID="4126" linkType="Drug"&gt;pioglitazone&lt;/ulink&gt; (Actos) controlled blood sugar and reduced HbA1c [&lt;ulink linkID="984737" linkType="Reference"&gt;984737&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2005, the drug was in phase III trials in Japan for type 2 diabetes in combination with biguanides [&lt;ulink linkID="638194" linkType="Reference"&gt;638194&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2005, phase III trials of nateglinide in combination with insulin-sensitizing agents were underway by Yamanouchi [&lt;ulink linkID="617042" linkType="Reference"&gt;617042&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, data were presented on nateglinide-gliclazide time-sharing and combination therapy at the 61st ADA meeting in Philadelphia, PA. In a randomized, crossover, open trial, 48 patients with type 2 diabetes, both nateglinide-gliclazide time-sharing and combination therapy significantly improved fasting plasma glucose and glycated albumin without deterioration of postprandial plasma glucose [&lt;ulink linkID="412638" linkType="Reference"&gt;412638&lt;/ulink&gt;]. A second study showed that while the efficacy of acarbose as an antidiabetic agent was comparable to nateglinide, the latter may have greater clinical utility due to its superior side effect profile [&lt;ulink linkID="412595" linkType="Reference"&gt;412595&lt;/ulink&gt;], [&lt;ulink linkID="415122" linkType="Reference"&gt;415122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2000, results of a series of phase III studies were presented at the American Diabetes Association's 60th annual scientific sessions. In a 24-week study involving 685 patients with type 2 diabetes, researchers evaluated nateglinide in comparison to and in combination with metformin. Nateglinide controlled mealtime glucose spikes and reduced overall glucose levels, as measured by glycosylated hemoglobin (HbA1c). HbA1c decreased by 0.5% with nateglinide alone, 0.8% with metformin and 1.4% with the combination of nateglinide and metformin. Additionally, fasting plasma glucose (FPG) decreased 0.7 mM with nateglinide, 1.6 mM with metformin and 2.4 mM with the combination of nateglinide and metformin [&lt;ulink linkID="370527" linkType="Reference"&gt;370527&lt;/ulink&gt;], [&lt;ulink linkID="369634" linkType="Reference"&gt;369634&lt;/ulink&gt;]. Nateglinide also increased the first phase insulin secretion, and enhanced glucose clearance, in 21 patients with type 2 diabetes [&lt;ulink linkID="369643" linkType="Reference"&gt;369643&lt;/ulink&gt;]. Results demonstrating a reduction in HbA1c levels by nateglinide comparable to that achieved with metformin were also published in November 2000 in Diabetes Care [&lt;ulink linkID="390280" linkType="Reference"&gt;390280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A second, 24-week study involving 467 patients with type 2 diabetes examined nateglinide as add-on therapy in patients who did not achieve optimal glucose control on maximum daily doses of metformin. Researchers found significant reductions in HbA1c in patients treated with both combinations of nateglinide plus metformin compared to the metformin plus placebo group. HbA1c decreased by 0.4% with metformin plus nateglinide (60 mg) and 0.6% with metformin plus nateglinide (120 mg) [&lt;ulink linkID="370527" linkType="Reference"&gt;370527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In an additional study of patients with type 2 diabetes presented at the meeting, nateglinide caused reductions in HbA1c, when combined with troglitazone. Treatment with nateglinide monotherapy (120 mg before three meals) and troglitazone monotherapy (600 mg once daily) resulted in reductions in HbA1C of 0.6% with nateglinide and 0.8% with troglitazone. There were further reductions in HbA1c (1.7% from baseline) in patients treated with the combination of the two agents [&lt;ulink linkID="370527" linkType="Reference"&gt;370527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An 8-week study of 152 patients with type 2 diabetes compared the effects of nateglinide with glyburide, on mealtime glucose levels and insulin secretion. Patients were randomized to treatment with nateglinide (120 mg immediately before three meals) or glyburide (10 mg once daily). Nateglinide primarily reduced mealtime glucose levels, while glyburide reduced FPG. Nateglinide did not increase fasting insulin, as did glyburide [&lt;ulink linkID="370528" linkType="Reference"&gt;370528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A further study examined the role of early insulin secretion, by measuring beta-cell function and glucose elimination from the blood after a meal. Patients with type 2 diabetes received single doses of nateglinide (120 mg), glyburide (10 mg) or placebo. Nateglinide increased first phase and stimulated earlier second phase insulin secretion and improved glucose elimination from the blood with a low incidence of hypoglycemia [&lt;ulink linkID="370528" linkType="Reference"&gt;370528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Clinical data presented at the European Association for the Study of Diseases (EASD) in September 1999, indicated that nateglinide is beneficial in controlling mealtime glucose spikes and reducing glycosylated hemoglobin in patients with type 2 diabetes. The results also demonstrated nateglinide's excellent safety profile, and its low potential for hypoglycemia [&lt;ulink linkID="341483" linkType="Reference"&gt;341483&lt;/ulink&gt;]. Research results presented at the same meeting demonstrated that nateglinide corrected a pivotal metabolic defect in patients with type 2 diabetes. Nateglinide increased beta-cell responsiveness, restoring the natural pattern of insulin secretion at mealtimes [&lt;ulink linkID="341515" linkType="Reference"&gt;341515&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1999, results of several studies demonstrating the rapid onset and short duration of action on the beta-cell were presented at the 59th American Diabetes Association Scientific sessions in San Diego, CA [&lt;ulink linkID="328166" linkType="Reference"&gt;328166&lt;/ulink&gt;]. Results from a double-blind crossover study that compared daily glycemic and insulin profiles after various mealtime dose regimens of nateglinide showed that nateglinide administration before each meal was safe and well tolerated and has a rapid and shorter duration of action on the beta-cell than &lt;ulink linkID="4212" linkType="Drug"&gt;repaglinide&lt;/ulink&gt; [&lt;ulink linkID="329671" linkType="Reference"&gt;329671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a double-blind, placebo-controlled 12-week study involving type 2 diabetic patients (n = 289), nateglinide (30, 60, 120 and 180 mg) given 10 min before main meals improved glycemic control (HbA1c reduction of up to 0.6%), and resulted in an FPG decrease of up to 1.2 mM (120 mg) or 0.8 mM (180 mg) [&lt;ulink linkID="299345" linkType="Reference"&gt;299345&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Preliminary phase II results showed that the drug's efficacy at 12 weeks was similar to that of troglitazone at 12 or 26 weeks, and other hypoglycemic agents at 52 weeks. It was well tolerated and showed no evidence of serious adverse events.&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2009, preclinical data on nateglinide were presented at the 69th ADA scientific sessions in New Orleans, LA. In spontaneously obese-diabetic OLETF rats treated with 50 mg/kg of nateglinide, 3 mg/kg of sitagliptin or a combination of both a long-term beneficial effect on hepatic insulin sensitivity and an improvement in the preservation of pancreatic beta cell function was demonstrated [&lt;ulink linkID="1013492" linkType="Reference"&gt;1013492&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Binding studies suggest that nateglinide competitively binds to the glibenclamide binding site on the sulfonyl urea receptor (SUR1). The inability to directly measure nateglinide binding using various assay methods suggests that nateglinide dissociates rapidly from SUR1 (estimated off-rate of 17 min; half-life of 0.04 min) [&lt;ulink linkID="295936" linkType="Reference"&gt;295936&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-09-28T00:00:00.000Z</StatusDate><Source id="630867" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-30T00:00:00.000Z</StatusDate><Source id="1351928" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-10T00:00:00.000Z</StatusDate><Source id="1329963" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-12-31T00:00:00.000Z</StatusDate><Source id="966663" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25218">Aventis Pharma AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-01-01T00:00:00.000Z</StatusDate><Source id="350762" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-10T00:00:00.000Z</StatusDate><Source id="1261697" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-31T00:00:00.000Z</StatusDate><Source id="931770" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-05-31T00:00:00.000Z</StatusDate><Source id="1355445" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-13T00:00:00.000Z</StatusDate><Source id="392881" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13794">Ajinomoto Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-08-30T00:00:00.000Z</StatusDate><Source id="338592" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-13T00:00:00.000Z</StatusDate><Source id="398723" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-17T00:00:00.000Z</StatusDate><Source id="1458968" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-06-01T00:00:00.000Z</StatusDate><Source id="420293" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-06-01T00:00:00.000Z</StatusDate><Source id="420293" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-13T00:00:00.000Z</StatusDate><Source id="392881" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-09-02T00:00:00.000Z</StatusDate><Source id="338592" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="1509402" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-09-28T00:00:00.000Z</StatusDate><Source id="630867" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23970">Britannia Pharmaceuticals Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-31T00:00:00.000Z</StatusDate><Source id="1251375" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-05-03T00:00:00.000Z</StatusDate><Source id="1362558" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-07-31T00:00:00.000Z</StatusDate><Source id="1517391" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-07-17T00:00:00.000Z</StatusDate><Source id="1452079" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-03T00:00:00.000Z</StatusDate><Source id="1456057" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-03T00:00:00.000Z</StatusDate><Source id="1449138" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-03T00:00:00.000Z</StatusDate><Source id="1352473" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13794">Ajinomoto Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-08-18T00:00:00.000Z</StatusDate><Source id="259573" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13794">Ajinomoto Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><Source id="189988" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-08-18T00:00:00.000Z</StatusDate><Source id="259573" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><Source id="189988" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-27T00:00:00.000Z</StatusDate><Source id="394704" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-10-06T00:00:00.000Z</StatusDate><Source id="384984" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13794">Ajinomoto Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-19T00:00:00.000Z</StatusDate><Source id="1261700" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-23T00:00:00.000Z</StatusDate><Source id="351318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-23T00:00:00.000Z</StatusDate><Source id="351318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-05-01T00:00:00.000Z</StatusDate><Source id="244117" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-05-01T00:00:00.000Z</StatusDate><Source id="244117" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="337451" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23970">Britannia Pharmaceuticals Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-08-18T00:00:00.000Z</StatusDate><Source id="259573" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-06T00:00:00.000Z</StatusDate><Source id="404307" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-05-01T00:00:00.000Z</StatusDate><Source id="244117" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26133">Roussel Morishita Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-09-02T00:00:00.000Z</StatusDate><Source id="338592" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26133">Roussel Morishita Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-08-18T00:00:00.000Z</StatusDate><Source id="259573" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26133">Roussel Morishita Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><Source id="189988" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00255"><Name>Calcium channel</Name><SwissprotNumbers><Swissprot>P50077</Swissprot><Swissprot>Q25452</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01591"><Name>Potassium channel</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13794">Ajinomoto Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>8</CountTotal></Company><Company><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20236">Stada Arzneimittel AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC([C@H]1CC[C@@H](CC1)C(=O)N[C@@H](C(=O)O)Cc2ccccc2)C</Smiles></StructureSmiles><Deals><Deal id="119040" title="Sandoz to develop and market Ajinomoto's nateglinide in certain territories worldwide "></Deal><Deal id="119041" title="Merck KGaA and Novartis to comarket nateglinide in Europe and certain other territories"></Deal><Deal id="119042" title="Yamanouchi to codevelop Ajinomoto's nateglinide in Japan "></Deal><Deal id="119043" title="Sankyo to comarket Ajinomoto's nateglinide in Japan"></Deal><Deal id="119044" title="Il Dong to develop Ajinomoto's nateglinide in South Korea  "></Deal><Deal id="119045" title="Roussel Morishita to develop Ajinomoto's nateglinide for type II diabetes "></Deal><Deal id="121369" title="Britannia and Ajinomoto to codevelop nateglinide in the UK and Ireland"></Deal><Deal id="142066" title="Ajinomoto to conduct clinical study for combined therapy of DDP-4 inhibitor and nateglinide in Japan with Astellas Pharma "></Deal><Deal id="142067" title="Mochida to commercialize Ajinomoto's Fastic tablet   "></Deal></Deals><PatentFamilies><PatentFamily id="104034" number="US-20030114389" title="Combination of organic compounds"></PatentFamily><PatentFamily id="1166147" number="WO-00215892" title="Combinations"></PatentFamily><PatentFamily id="1167816" number="WO-2007119580" title="Process for production of carboxylic acid chloride compound"></PatentFamily><PatentFamily id="1213744" number="WO-00234254" title="Nateglinide-containing preparations"></PatentFamily><PatentFamily id="1354877" number="WO-09822105" title="Tabletted preparation"></PatentFamily><PatentFamily id="1390586" number="AT-00149483" title="Kristalle Von N-(Trans-4- Isopropylcyclohexylcarbonyl)-D-Phenylalanin Und Verfahren Zu Ihrer Herstellung"></PatentFamily><PatentFamily id="1390586" number="US-05463116" title="Crystals Of N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenylalanine And Methods For Preparing Them"></PatentFamily><PatentFamily id="1390586" number="JP-02508949" title="Crystal Of N-(trans-4-Isopropylcyclohexylcarbonyl)-D-Phenylalanine And Its Production"></PatentFamily><PatentFamily id="1390586" number="ES-02100291" title="Cristales De N-(Trans-4-Isopropilciclohexilcarbonil)-D-Fenilalanina Y Metodos Para Prepararlos."></PatentFamily><PatentFamily id="1390586" number="US-05488150" title="Crystals Of N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenylalanine And Methods For Preparing Them"></PatentFamily><PatentFamily id="1390586" number="DE-69217762" title="Kristalle Von N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenylalanin Und Verfahren Zu Ihrer Herstellung"></PatentFamily><PatentFamily id="1390586" number="EP-00526171" title="Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them."></PatentFamily><PatentFamily id="1441241" number="WO-2007091623" title="Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis"></PatentFamily><PatentFamily id="1472320" number="WO-02072146" title="Combination of organic compounds"></PatentFamily><PatentFamily id="1477213" number="WO-2008066026" title="Therapeutic agent for diabetes"></PatentFamily><PatentFamily id="1534126" number="WO-00147557" title="Oral preparations for diabetes"></PatentFamily><PatentFamily id="1604100" number="EP-01741445" title="Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents"></PatentFamily><PatentFamily id="1604100" number="EP-01743655" title="Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents"></PatentFamily><PatentFamily id="1604100" number="EP-01741447" title="Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents"></PatentFamily><PatentFamily id="1604100" number="WO-00152825" title="Combinations comprising dipeptidylpeptidase-IV inhibitor"></PatentFamily><PatentFamily id="178224" number="WO-03076393" title="Salts of nateglinide"></PatentFamily><PatentFamily id="1829674" number="WO-00232853" title="Process For The Preparation Of Acylphenylalanines"></PatentFamily><PatentFamily id="1899497" number="WO-00126639" title="Method of treating metabolic disorders"></PatentFamily><PatentFamily id="1903425" number="US-06830759" title="Antidiabetic preparation for oral administration"></PatentFamily><PatentFamily id="2051466" number="WO-00232854" title="Process for producing nateglinide crystal"></PatentFamily><PatentFamily id="207436" number="WO-03099332" title="Medicinal composition for inhibiting the expression of ATP-citrate lyase and use thereof"></PatentFamily><PatentFamily id="2163270" number="EP-00196222" title="Hypoglycemic agent."></PatentFamily><PatentFamily id="2163270" number="US-00034878" title="Hypoglycemic Agent"></PatentFamily><PatentFamily id="2270160" number="WO-03080070" title="Combination of organic compounds"></PatentFamily><PatentFamily id="2276405" number="WO-00121159" title="Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes"></PatentFamily><PatentFamily id="2360284" number="WO-2005013964" title="Pharmaceutical preparation containing nateglinide"></PatentFamily><PatentFamily id="2360284" number="JP-04947820" title="Nateglinide containing formulation"></PatentFamily><PatentFamily id="254067" number="WO-2005092363" title="Preventive/remedy for diabetic complications using oligopeptide"></PatentFamily><PatentFamily id="283277" number="WO-03087039" title="Novel nateglinide crystal"></PatentFamily><PatentFamily id="326080" number="WO-00234713" title="Process for producing B-form nateglinide crystal"></PatentFamily><PatentFamily id="401676" number="WO-2005049006" title="Remedy for diabetes"></PatentFamily><PatentFamily id="44648" number="JP-2007099764" title="Hypoglycemic agent"></PatentFamily><PatentFamily id="493830" number="WO-00215933" title="Combination"></PatentFamily><PatentFamily id="621190" number="WO-00168136" title="Drugs for complications of diabetes and neuropathy and utilization thereof"></PatentFamily><PatentFamily id="654188" number="WO-00147514" title="Use of hypoglycemic agent for treating impaired glucose metabolism"></PatentFamily><PatentFamily id="669611" number="TW-0I308875" title="Pharmaceutical composition containing nateglinide for the prevention or delay of the progression to overt diabetes"></PatentFamily><PatentFamily id="695230" number="WO-00240010" title="Nateglinide-containing hydrophilic drug preparations"></PatentFamily><PatentFamily id="696641" number="WO-2004082402" title="Compositions comprising fatty acids and amino acids"></PatentFamily><PatentFamily id="845756" number="WO-2006016602" title="Nateglinide-containing preparation reduced in bitterness"></PatentFamily><PatentFamily id="874781" number="WO-03087038" title="Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine"></PatentFamily><PatentFamily id="877747" number="WO-2005094812" title="Nateglinide-containing preparation"></PatentFamily><PatentFamily id="917602" number="WO-03008367" title="Process for the manufacture of organic compounds"></PatentFamily><PatentFamily id="92420" number="JP-07017899" title="Production Of Carboxylic Acid Chloride"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>17</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>16</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>30</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>40</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Fosun Pharmaceutical (Group) Co Ltd" id="1015871"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Soleno Therapeutics Inc" id="1017301"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharma Holdings Inc" id="1022451"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="First Southwest Pharmaceutical Factory" id="1028563"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="C-TRI Korea" id="1030159"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Ausa Pharmed Co Ltd" id="1035805"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mundipharma International Corp Ltd" id="1045514"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Globe Pharmaceutical Co Ltd" id="1047041"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Huatuo Medical Science Co Ltd" id="1047783"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Auven Therapeutics" id="1053946"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mirae Fine Chemical Co. Ltd." id="1054660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin KingYork Group" id="1056725"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Krisani Biosciences (P) Ltd" id="1066295"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Aoyipollen Pharmaceutical Co Ltd" id="1068303"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hefei Huafang Medical Technology Co Ltd" id="1072314"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Shuren University" id="1075903"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Dongcheng Institute for Drug Control" id="1076229"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Meheco Co Ltd" id="1080978"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neutec Pharmaceuticals" id="1084359"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Juxing Kanghua Yiyao Co Ltd" id="1084409"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cellix Bio Pvt Ltd" id="1112810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avadel Pharmaceuticals plc" id="1128249"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Renhong Medical Technology Co Ltd" id="1145338"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Zhangmeng Network Technology Co Ltd" id="1147029"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ajinomoto Co Inc" id="13794"></CompanyLink><CountAsOwner>23</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>23</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BASF SE" id="14356"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CJ Corp" id="15473"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novo Nordisk A/S" id="18614"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gedeon Richter Ltd" id="19441"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stada Arzneimittel AG" id="20236"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>21</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>21</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>19</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>19</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daewon Pharm Co Ltd" id="23350"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kurume University" id="24985"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BZL Biologics Inc" id="27772"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Elixir Pharmaceuticals Inc" id="29725"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cadila Pharmaceuticals Ltd" id="30025"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neuland Laboratories Ltd" id="30189"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AMSA Anonima Materie Sintetiche e Affini SpA" id="30770"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ind-Swift Ltd" id="31515"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>